

Contractile Activity and Prostacyclin Generation in Isolated Coronary Arteries from Diabetic Dogs

L. Sterin-Borda, E. S. Borda, M. F. Gimeno, M. A. Lazzari, E. del Castillo and A. L. Gimeno

Centro de Estudios Farmacológicos y de Principios Naturales, Consejo Nacional de Investigaciones Científicas y Técnicas and Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Buenos Aires, Argentina

Summary. The present study was aimed at determining the generation of 'prostacyclin (PGI₂)-like-material' in coronary arteries from normal and diabetic (pancreatectomized) dogs as well as the contractile responses to prostacyclin of preparations from normal, diabetic and insulin-treated diabetic animals. PGI₂ produced a dose-dependent relaxation of coronary arteries from normal dogs. In contrast, those from diabetic animals were not relaxed; indeed, at low concentrations PGI₂ failed to evoke any effect but at higher ones it induced a distinct contraction. In arteries from diabetic animals treated with insulin, PGI₂ induced a biphasic contractile effect, which lay between that of normal controls and untreated diabetics. In addition the basal generation of 'PGI₂-like-material' by coronary arteries was significantly higher in the diabetic (141 ± 0.2 pg/mg, mean \pm SEM) than in normal dogs (59 ± 0.2 pg/mg). The present experiments demonstrate that the generation of 'PGI₂-like-substance' is significantly increased in coronary arteries from diabetic dogs, but the same vessels are unable to respond to added authentic PGI₂ with relaxation; on the contrary they react with a distinct positive contractile response.

Key words: Isolated coronary arteries, diabetes, prostacyclin, PGI₂ generation, coronary constriction, coronary relaxation, pancreatectomized dogs.

Prostacyclin (PGI₂) is a labile prostaglandin which can be synthesized by several vascular tissues [1], including coronary vessels [2–4]. PGI₂ is a potent inhibitor of platelet aggregation [1, 5] and is also able to relax a variety of isolated arteries [2, 6–9].

Alterations in vascular function and increased platelet aggregation have been suggested as factors involved in the vasculopathy that accompanies diabetes [10, 11]. In addition it has been reported that vas-

cular smooth muscle from diabetic animals shows changes in reactivity to vasoconstrictor agents [12].

In view of these findings it was decided to investigate the possible importance of PGI₂ in the coronar-arteries of diabetic dogs. Firstly the reactivity to PGI₂ of isolated normal, diabetic and insulin-treated diabetic dog coronary vessels was examined, and secondly the generation of 'PGI₂-like-material' in vitro by coronary arteries from diabetic and normal dogs was determined.

Subjects and Methods

Animals

Coronary arteries were obtained from dogs weighing between 9 and 20 kg. Three different groups of animals were used: a) normal ($n = 6$); b) totally pancreatectomized ($n = 6$) and c) totally pancreatectomized injected with insulin ($n = 3$). Experiments were performed 5–7 days after the operation and approximately 16 h following the last meal [13]. The pancreatectomized dogs were fed with raw beef heart ad libitum, and 70 g of raw pancreas daily [13]. Normal and insulin-treated dogs were fed with the same food. Pancreatectomized animals not treated with insulin developed hyperglycaemia and ketosis.

Some of the totally pancreatectomized dogs were given soluble insulin (E. Lilly) in doses of 0.5 to 1.0 unit \cdot kg⁻¹ \cdot day⁻¹ at 0800 h for 5 days, but the hormone was discontinued 2 h before sacrifice. Blood glucose was determined at the time of sacrifice (1000 h) by the Somogyi method. As previously reported mean blood glucose concentration (\pm SEM) was normal in control dogs (5.7 ± 0.5 mmol/l, $n = 6$) and significantly elevated in pancreatectomized animals (18.4 ± 1.3 mmol/l, $n = 6$) [13]. Dogs were anaesthetised with pentobarbital (25–30 mg/kg, IV) and the beating heart was rapidly removed from the chest [14].

Coronary Artery Preparations

After excision of the heart, the aortic root and its attached left anterior descending and circumflex arteries were dissected en bloc, completely cleaned of surrounding (non-arterial) tissue and immediately immersed in Krebs-Ringer-bicarbonate (KRB) solution at pH 7.4, composed as reported elsewhere [15]. A coronary artery

Table 1. Basal resting tension or initial pre-load of the isolated coronary arteries after equilibration for 90 min

Experimental animals	Basal resting tension (mg)
Normal dogs	627 ± 25 (n = 9)
Pancreatectomized dogs	598 ± 17 (n = 12)
Pancreatectomized dogs receiving insulin	619 ± 20 (n = 5)

Values are expressed as mean ± SEM. They represent the basal tensions recorded before the addition of drugs. n = number of strips tested




Fig. 1. Cumulative dose-response curves of PGI₂ on the tension developed by isolated coronary arterial strips from: ●—● normal dogs; ○—○ diabetic dogs untreated with insulin; and ○—○ diabetic dogs treated with insulin. Points and bars represent mean ± SEM, respectively. Figures in parentheses indicate the number of preparations

from each dog was cut in segments and one to four strips were used for the measurement of contractile activity and others to test their platelet anti-aggregatory capacity.

Tonic Changes of Isolated Coronary Arteries

Arterial strips 2 cm long, which ranged between 20 and 26 mg in blotted wet weight, were cut helically and mounted in a muscle chamber containing 20 ml KRB solution, gassed with 5% CO₂ in oxygen and kept at 37 °C and pH 7.4. The contractile activity was recorded as previously reported [14, 16]. Briefly one end of the strips was attached to a glass holder and the other was connected by means of a thread to a force transducer coupled to an oscillographic recorder via a carrier preamplifier.

Under an initial preload of 1 g the strips were allowed to equilibrate for 90 min. After this equilibration arteries underwent a stress relaxation and tension stabilized around 600 mg. At 90 min there were no significant differences in basal resting tone between the three groups (Table 1). The tonic changes of the vessels elicited by experimental additions were expressed as mg of tension above or below the basal resting tensions or initial preloads (0 mg in the figures).

Cumulative dose-response curves for PGI₂ were constructed for untreated control coronary arteries as well as for those previously exposed to haloperidol or phentolamine. A stock solution was made daily, using Tris buffer at pH 9.3. All PGI₂ solutions were kept at 0–4 °C and the drug was added directly to the muscle chamber every 5 min. Haloperidol 10⁻⁷ mol/l (Haldol, McNeil) or phentolamine 10⁻⁵ mol/l (Regitine, Ciba) were delivered into the tissue bath 30 min before PGI₂.

Determination of 'PGI₂-Like-Material'

Strips of coronary arteries (20–25 mg dry weight) were incubated for 20 min in 200 µl of KRB at room temperature and at pH 8.0 ± 0.1. The supernatant from each reaction mixture was removed and 50 µl of the incubate were placed in the cuvette of an aggregometer containing platelet-rich plasma from blood donors. The addition was made 45 s before adding adenosine diphosphate at 5 µmol/l as the aggregating agent. Light transmission through the sample was recorded as a measurement of aggregation. The inhibition of aggregation by the tissue supernatant was quantitated against the anti-aggregatory effect of standardized prostacyclin dissolved in Tris buffer 0.05 mol/l (pH 9.0) on the day of the experiment. The amount of 'PGI₂-like-material' generated by strips of coronary arteries was calculated and expressed as PGI₂-equivalence in pg/mg dry weight. When anti-aggregatory activity was detected in the samples they were retested after incubation for 30 min at 37 °C. All measurements of all the groups were made in the same platelet-rich plasma. Further details have been reported elsewhere [16, 17]. It must be stressed that despite the limitations of bioassay, it is extremely useful in many experimental conditions, particularly when the aim is to follow changes in the concentration of prostaglandins rather than measuring absolute levels.

Statistics

Results were compared using Student's 't' test. Means were considered significantly different when *p* = 0.05 or less. Results are presented as mean ± SEM.

Results

Effects of PGI₂ on the Basal Tone of Isolated Dog Coronary Arteries

Figure 1 shows the cumulative dose-response curves of PGI₂ versus the tension developed by isolated coronary arteries from normal, pancreatectomized and insulin-treated pancreatectomized dogs. It can be seen that PGI₂ produced a dose-dependent decrement of basal tone of isolated coronary arteries from normal dogs, whereas in coronary preparations from diabetic animals PGI₂ at low concentrations (from 10⁻⁹ up to 5 × 10⁻⁸ mol/l) had no effect and at higher ones (10⁻⁷ to 10⁻⁵ mol/l) evoked an enhancement

Table 2. Influence of phentolamine or haloperidol on the effect of PGI₂ on isolated coronary arteries from normal and diabetic dogs

	Normal dogs			Diabetic dogs		
	PGI ₂ (mol/l)					
	10 ⁻⁸	10 ⁻⁷	10 ⁻⁶	10 ⁻⁸	10 ⁻⁷	10 ⁻⁶
No drug	-45 ± 12	-89 ± 8	-96 ± 6	0 ± 0	+14 ± 1	+87 ± 9
Phentolamine (10 ⁻⁵ mol/l)	-42 ± 10	-88 ± 9	-99 ± 7	0 ± 0	+12 ± 1	+92 ± 8
Haloperidol (10 ⁻⁷ mol/l)	-47 ± 14	-86 ± 11	-94 ± 5	0 ± 0	+15 ± 2	+95 ± 7

Values expressed as mg of tension above and below the basal resting tone. Results expressed as mean ± SEM ($n = 5$ in each group). Phentolamine and haloperidol did not modify the basal tone

of basal tone proportional to the dose. In preparations from insulin-treated diabetic dogs PGI₂ elicited a biphasic effect: relaxation at low concentrations and stimulation at higher ones. Both influences lay between those observed in untreated pancreatectomized and normal control animals. Figure 2 shows direct oscillographic tracings of the effects of PGI₂ on coronary arteries from normal and pancreatectomized diabetic dogs.

Preincubation for 30 min with phentolamine (10⁻⁵ mol/l) or haloperidol (10⁻⁷ mol/l) failed to block the stimulating effect of PGI₂ on isolated coronary arteries from diabetic dogs (Table 2).

Generation of 'PGI₂-Like-Material' by Isolated Dog Coronary Arteries

Table 3 shows the comparative production of 'PGI₂-like-material' by coronary arteries isolated from normal and diabetic dogs. The basal release of 'PGI₂-like-substance' by coronary strips from diabetic dogs was significantly greater than in preparations from normal dogs ($p = 0.001$).

Discussion

The present study shows that coronary arteries isolated from diabetic dogs exhibit a contractile response to PGI₂ different from that of preparations from normal animals. Furthermore, isolated coronary arteries from diabetic animals generate an increased amount of 'PGI₂-like-material' compared with controls.

Prostacyclin produced a dose-dependent relaxation of coronary arteries isolated from normal dogs, this being in keeping with reports of studies in vivo [18–20]. However, isolated coronary arteries from diabetic dogs were unable to respond with relaxation following PGI₂. Indeed, at low concentrations prostacyclin failed to evoke any effect, whereas at higher ones it induced a distinct contraction.


An alteration in the vascular contractile effects of noradrenaline and 5-hydroxytryptamine has recently been shown in diabetic rats. The effect of noradrena-

Table 3. Release of 'PGI₂-like material' by coronary arteries isolated from normal and diabetic dogs

Condition	'PGI ₂ -like material' ^a
Normal	59 ± 0.2 ($n = 6$)
Diabetic	141 ± 2.5 ($n = 5$)

^a Values expressed as pg/mg dry weight (mean ± SEM); $n =$ number of strips tested.

'PGI₂-like material' was characterized by the anti-aggregatory capacity against ADP-induced aggregation of platelet rich plasma detected after 20 min at room temperature, and absence of anti-aggregation with samples incubated for 30 min at 37 °C

**Fig. 2.** Direct tracings showing the contractile response to PGI₂ (mol/l) of coronary artery strips isolated from a normal and a diabetic dog

line was greatly increased in diabetic aorta while the response to 5-hydroxytryptamine was significantly decreased [12]. In addition, it has been demonstrated that the stimulating action of PGI₂ may be linked to the release of noradrenaline and to an alpha adrenoceptive mechanism [21–23]. The fact that in isolated coronary arteries from the diabetic dogs the vasoconstrictor influence of PGI₂ was not blocked either by phentolamine or by haloperidol suggests that this ef-

fect does not result from an enhancement in prostacyclin-induced release of neurotransmitters.

In diabetic animals treated with insulin a concentration-dependent biphasic effect of PGI₂ (relaxation and contraction) was observed. However, both responses were attenuated and lay between those of normal controls and untreated diabetics.

To test whether diabetes has a direct effect on the release of prostacyclin, we have investigated the 'PGI₂-like-material' generated by isolated diabetic dog coronary arteries. A significantly higher production of 'PGI₂-like-substance' was observed in the diabetic condition than in controls. This is in agreement with findings in perfused hearts of acutely diabetic rats [24]. However, there are several reports describing decreased prostacyclin production in diabetes [25, 26]. Experimental animals lose considerable amounts of body fat during the first few days following induction of diabetes and it is possible that the availability of substrates for prostaglandin synthesis may therefore be increased during this period. This could possibly explain the differences in PGI₂ production between the different reports, since in both the present study and in the experiments already quoted [24] animals were used within a few days after the induction of diabetes.

In view of the aforementioned results the exact role of PGI₂ in coronary vascular complications of diabetes remains unclear.

Acknowledgements. This work was supported by Grant 6638 from the 'Consejo Nacional de Investigaciones Científicas y Técnicas de la República Argentina'. PGI₂ was kindly provided by Dr. J. Pike (Upjohn, Kalamazoo, Michigan, USA).

References

- Moncada S, Higgs EA, Vane JR (1977) Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. *Lancet* 1: 18–20
- Dusting GF, Moncada S, Vane JR (1977) Prostacyclin is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachidonic acid. *Prostaglandins* 13: 3–15
- Schrör K, Moncada S, Ubatuba FB, Vane JR (1977) Formation of prostacyclin causes decrease in coronary vascular resistance during application of arachidonic acid in the rabbit isolated heart. *Naunyn Schmiedeberg's Arch Pharmacol* 297: R31
- Schrör K, Moncada S, Ubatuba FB, Vane JR (1978) Transformation of arachidonic acid and prostaglandin endoperoxide by the guinea pig heart. Formation of RCS and prostacyclin. *Eur J Pharmacol* 47: 103–114
- Moncada S, Gryglewsky R, Bunting S, Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. *Nature* 263: 663–665
- Pomerantz K, Sintetos A, Ramwell P (1978) The effect of prostacyclin on the human umbilical artery. *Prostaglandins* 15: 1035–1044
- Chapeau CE, White RP (1979) Effects of prostacyclin on the canine isolated basilar artery. *Prostaglandins* 17: 573–580
- Schrör K, Rösen P (1979) Prostacyclin (PGI₂) decreases the cyclic AMP level in coronary arteries. *Naunyn Schmiedeberg's Arch Pharmacol* 306: 101–103
- Ogletree ML, Smith BJ, Lefer AM (1978) Actions of prostaglandins on isolated perfused cat coronary arteries. *Am J Physiol* 235: 400–406
- Bern MB (1978) Platelet functions in diabetes mellitus. *Diabetes* 27: 342–352
- Colwell JA, Chambers A, Laimins M (1975) Increased platelet aggregation in early diabetes. *Diabetes* 24: 684–687
- Owen MP, Carrier GO (1979) Alteration in vascular smooth muscle sensitivity to vasoconstrictor agents by streptozotocin induced diabetes. *Proc West Pharmacol Soc* 22: 363–366
- del Castillo EJ, Galli ME, Roldán A, Riatti CT, Houssay BA (1965) Decrease in Ketonemia due to infusion of lipids in pancreatectomized dogs. *Diabetes* 14: 33–35
- Borda L, Schuchleib R, Henry P (1977) Effect of potassium on isolated canine coronary arteries. *Circ Res* 41: 778–786
- Sterin-Borda L, Gimeno AL, Gimeno MF (1974) Frequency-force relationship on isolated rat and guinea pig atria. Effect of cholinergic and adrenergic receptor antagonists. *Proc Soc Exp Biol Med* 145: 1151–1157
- Gimeno MF, Sterin-Borda L, Borda ES, Lazzari MA, Gimeno AL (1980) Human plasma transforms prostacyclin (PGI₂) into a platelet antiaggregatory substance which contracts isolated bovine coronary arteries. *Prostaglandins* 19: 907–916
- Borda ES, Lazzari MA, Gimeno MF, Gimeno AL (1980) Human platelet rich plasma and human serum protects from inactivation the antiaggregatory capacity of prostacyclin-like material (PGI₂) produced by the rat stomach fundus. *Prostaglandins* 19: 899–905
- Dusting GJ, Chapple DJ, Hughes R, Moncada S, Vane JR (1978 a) Prostacyclin (PGI₂) induces coronary vasodilatation in anaesthetized dogs. *Cardiovasc Res* 12: 720–730
- Dusting GJ, Moncada S, Vane JR (1978 b) Recirculation of prostacyclin (PGI₂) in the dog. *Br J Pharmacol* 64: 315–320
- Fitzpatrick TM, Alter I, Corey EJ, Ramwell PW, Rose JC, Kot PA (1978) Cardiovascular responses to PGI₂ (prostacyclin) in the dog. *Circulation Res* 42: 192–194
- Borda LS, Canga L, Gimeno MF, Gimeno AL (1979) Adrenergic mechanism subserving a positive inotropism and chronotropism of prostacyclin on isolated rat atria. *Experientia* 35: 529–531
- Borda ES, Agostini MC, Sterin-Speziale N, Gimeno MF, Gimeno AL (1979) Spontaneous contractile activity of isolated ovarian human vein. Influence of prostacyclin (PGI₂). *Prostaglandins* 18: 829–935
- Herman AG, Verbeurens TJ, Moncada S, Vane JR, Vanhoutte PM (1978) Effect of prostacyclin on myogenic activity and adrenergic neuroeffector interaction in isolated canine veins. *Arch Int Pharmacodyn Ther* 232: 340–341
- Rösen P, Schrör K (1980) Increased prostacyclin release from perfused hearts of acutely diabetic rats. *Diabetologia* 18: 391–394
- Harrison HE, Reece AH, Johnson M (1978) Decreased vascular prostacyclin in experimental diabetes. *Life Sci* 33: 351–356
- Silberbauer K, Scherthaner G, Sinzinger H, Piza-Katzer H (1979) Decreased vascular prostacyclin in juvenile onset diabetics. *N Engl J Med* 300: 366–367

Received: 24 September 1980
and in revised form: 11 June 1981

Dr. A. L. Gimeno
Centro de Estudios Farmacológicos y de Principios Naturales (CEFAPRIN)
Serrano 665/69
1414 Buenos Aires, Argentina